

Blood-Brain Barrier: Function, Dysfunction, Therapeutics

David Rossi

Department of Neurovascular Research, University of Rome, Rome, Italy

Corresponding Authors*

David Rossi

Department of Neurovascular Research, University of Rome, Rome, Italy

E-mail: david.rossi@uniroma.it

Copyright: 2025 David Rossi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 01-Jul-2025; **Accepted:** 08-Aug-2025; **Published:** 08-Aug-2025

Introduction

The Blood-Brain Barrier (BBB) is more than just a physical wall; it's a dynamic part of the neurovascular unit, actively regulating brain homeostasis. Recent insights highlight its complex involvement in a range of neurological diseases, from stroke to neurodegenerative conditions, driving research into novel therapeutic strategies that target its specific components and functions [1].

Overcoming the blood-brain barrier is a major challenge for Central Nervous System (CNS) drug delivery. Recent progress includes diverse strategies like osmotic disruption, focused ultrasound, and receptor-mediated transcytosis. Nanocarriers are also gaining traction, offering precise targeting and payload release to effectively deliver therapeutics past this crucial biological barrier [2].

Microvascular endothelial cells are central to the blood-brain barrier's integrity, forming tight junctions and orchestrating transport. Their precise regulation is vital for brain health. Disruptions in these cells, however, are implicated in numerous neurological disorders, highlighting them as key targets for understanding and treating cerebrovascular pathologies [3].

Manipulating the blood-brain barrier for drug delivery has evolved significantly, moving from traditional osmotic and direct injection methods to innovative strategies. These include highly targeted nanoparticles, receptor-mediated transport systems, and transient BBB disruption techniques, all aimed at enhancing therapeutic efficacy for neurological disorders while minimizing systemic side effects [4].

The blood-brain barrier, essential for maintaining cerebral homeostasis, is a complex interface whose integrity is critical for neurological health. Its breakdown is increasingly recognized as a key event in the pathogenesis of various neurological diseases, including neuroinflammation, neurodegeneration, and stroke, providing therapeutic targets for future interventions

[5].

Blood-brain barrier disruption is not merely a symptom but an active participant in the pathology of many Central Nervous System disorders. Understanding the mechanisms behind its breakdown, including inflammation and oxidative stress, offers new avenues for therapeutic intervention. Restoring BBB integrity or selectively modulating its permeability holds significant promise for improving outcomes in neurological conditions [6].

The blood-brain barrier's integrity relies fundamentally on tight junctions that seal the paracellular space, preventing uncontrolled solute movement. Active efflux transporters, crucial for expelling toxins, also contribute significantly. Together, these components, within the broader neurovascular unit, dictate selective permeability, making them vital targets for research into brain drug delivery and disease [7].

Neuroinflammation and blood-brain barrier dysfunction are deeply intertwined, particularly in the context of Alzheimer's disease. The breakdown of the BBB permits infiltration of peripheral immune cells and molecules, exacerbating chronic neuroinflammation. This interplay forms a vicious cycle, contributing significantly to amyloid-beta pathology and neuronal damage, presenting crucial targets for disease modification [8].

The blood-brain barrier's integrity is increasingly recognized as a key factor in Parkinson's disease pathophysiology. Dysfunction of the BBB in PD contributes to neuroinflammation, oxidative stress, and impaired clearance of neurotoxic proteins, accelerating dopaminergic neurodegeneration. Modulating BBB function offers promising therapeutic avenues for future interventions in this complex disorder [9].

Blood-brain barrier dysfunction is increasingly recognized as a crucial player in the initiation and progression of epilepsy. A compromised BBB can lead to the extravasation of albumin and other blood components into the brain, directly contributing to neuronal hyperexcitability and epileptogenesis. Targeting BBB integrity thus offers a novel therapeutic strategy for managing epileptic disorders [10].

Description

The Blood-Brain Barrier (BBB) is a dynamic part of the neurovascular unit, not just a physical wall. It actively regulates brain homeostasis [1]. Microvascular endothelial cells are central to BBB integrity, forming tight junctions and orchestrating transport vital for brain health [3]. Its integrity relies fundamentally on tight junctions, sealing the paracellular space and preventing uncontrolled solute movement [7]. Active efflux transporters, crucial for expelling toxins, contribute significantly. These components within the neurovascular unit dictate selective permeability, making them vital targets for research [7].

The BBB, essential for maintaining cerebral homeostasis, is a complex in-

interface whose integrity is critical for neurological health [5]. Its breakdown is increasingly recognized as a key event in the pathogenesis of various neurological diseases, including neuroinflammation, neurodegeneration, and stroke, providing therapeutic targets [5]. Blood-brain barrier disruption is not just a symptom; it's an active participant in the pathology of many Central Nervous System (CNS) disorders [6]. Understanding mechanisms like inflammation and oxidative stress behind its breakdown offers new avenues for therapy [6]. Restoring BBB integrity or selectively modulating its permeability holds significant promise for improving outcomes in neurological conditions [6].

Overcoming the BBB is a major challenge for CNS drug delivery [2]. Recent progress includes diverse strategies like osmotic disruption, focused ultrasound, and receptor-mediated transcytosis [2]. Nanocarriers are gaining traction, offering precise targeting and payload release to effectively deliver therapeutics past this crucial biological barrier [2]. Manipulating the BBB for drug delivery has evolved significantly, from traditional osmotic and direct injection methods to innovative strategies [4]. These include highly targeted nanoparticles, receptor-mediated transport systems, and transient BBB disruption techniques, all aimed at enhancing therapeutic efficacy for neurological disorders while minimizing systemic side effects [4].

Neuroinflammation and BBB dysfunction are deeply intertwined, particularly in Alzheimer's Disease [8]. Breakdown of the BBB permits infiltration of peripheral immune cells and molecules, exacerbating chronic neuroinflammation [8]. This forms a vicious cycle, contributing to amyloid-beta pathology and neuronal damage, presenting crucial targets for disease modification [8]. The BBB's integrity is a key factor in Parkinson's Disease (PD) pathophysiology [9]. Dysfunction of the BBB in PD contributes to neuroinflammation, oxidative stress, and impaired clearance of neurotoxic proteins, accelerating dopaminergic neurodegeneration [9]. Modulating BBB function offers promising therapeutic avenues for future interventions in this complex disorder [9].

BBB dysfunction is increasingly recognized as a crucial player in the initiation and progression of epilepsy [10]. A compromised BBB can lead to the extravasation of albumin and other blood components into the brain, directly contributing to neuronal hyperexcitability and epileptogenesis [10]. Targeting BBB integrity offers a novel therapeutic strategy for managing epileptic disorders [10].

Conclusion

The Blood-Brain Barrier (BBB) functions as a dynamic part of the neurovascular unit, essential for maintaining brain homeostasis and protecting the Central Nervous System (CNS). It involves microvascular endothelial cells, tight junctions, and active efflux transporters that collectively regulate selective permeability, crucial for brain health. However, BBB dysfunction is increasingly recognized as a pivotal factor in the pathogenesis of

various neurological diseases, including stroke, neuroinflammation, neurodegeneration, Alzheimer's Disease, Parkinson's Disease, and epilepsy. This breakdown is not just a symptom but actively contributes to disease pathology, exacerbating conditions through mechanisms like inflammation, oxidative stress, and the infiltration of peripheral immune components. For example, in Alzheimer's, BBB dysfunction intensifies neuroinflammation and amyloid-beta pathology, while in Parkinson's, it accelerates dopaminergic neurodegeneration. A compromised BBB in epilepsy can lead to neuronal hyperexcitability, promoting epileptogenesis. Because of its critical role, overcoming the BBB is a major challenge for CNS drug delivery. Researchers are developing innovative strategies such as osmotic disruption, focused ultrasound, receptor-mediated transcytosis, and targeted nanoparticles to enhance therapeutic efficacy and minimize systemic side effects. Targeting BBB integrity or modulating its permeability offers promising avenues for future neurological interventions.

References

1. Marco BA DZ, Arthur HN, Eng HL. The Blood-Brain Barrier in Health and Disease: *Recent Advances in Neurovascular Unit Biology*. *Trends Neurosci*. 2023;46:361-372.
2. Ying Y, Qing Y, Yi Z. Recent advances in blood-brain barrier disruption for enhanced CNS drug delivery. *Drug Deliv*. 2022;29:414-432.
3. Thomas MO, Amy LS, Jeffrey MG. Blood-brain barrier regulation by microvascular endothelial cells in health and disease. *Transl Stroke Res*. 2022;13:389-404.
4. Alessandra DM, Federica S, Andrea C. The blood-brain barrier and its manipulation for drug delivery: from tradition to innovation. *Expert Opin Drug Deliv*. 2022;19:639-657.
5. Zuzana PD, Ján B, Peter V. The blood-brain barrier in health and neurological disease. *Physiol Res*. 2021;70:1-13.
6. Yan L, Jing L, Xiangrong G. Blood-brain barrier disruption and its implications for central nervous system disorders. *Front Cell Neurosci*. 2021;15:702919.
7. Zsuzsa S, Krisztina N, Zsolt F. Tight Junctions, Transporters, and the Neurovascular Unit: Key Elements in Blood-Brain Barrier Function. *Int J Mol Sci*. 2021;22:5769.
8. Zoya F, Mahboobeh K, Maryam M. Blood-brain barrier and neuroinflammation: a focus on Alzheimer's disease. *Curr Neuropharmacol*. 2022;20:1362-1378.
9. Maria CM MM, Ricardo RP A, Cláudia SP A. Blood-Brain Barrier in Parkinson's Disease: *An Update on Its Role in Pathophysiology and Therapeutic Implications*. *Int J Mol Sci*. 2022;23:9646.
10. Jovana V, Vesna S, Milena J. The Role of Blood-Brain Barrier Dysfunction in Epilepsy. *Int J Mol Sci*. 2023;24:8608.